Holen Sie sich die Stockscreener-App
0.497
2.37%
0.0115
Handel nachbörslich:
.51
0.013
+2.62%
Schlusskurs vom Vortag:
$0.4855
Offen:
$0.51
24-Stunden-Volumen:
80,353
Relative Volume:
0.07
Marktkapitalisierung:
$3.68M
Einnahmen:
$686.00K
Nettoeinkommen (Verlust:
$-11.76M
KGV:
-0.1611
EPS:
-3.0856
Netto-Cashflow:
$-9.40M
1W Leistung:
-4.51%
1M Leistung:
-1.31%
6M Leistung:
+119.52%
1J Leistung:
-68.14%
1-Tages-Spanne:
$0.47
$0.51
1-Wochen-Bereich:
$0.46
$0.5498
52-Wochen-Spanne:
$0.0922
$12.00
Azitra Inc Stock (AZTR) Company Profile
Firmenname
Azitra Inc
Sektor
Branche
Telefon
203 646 6446
Adresse
21 Business Park Drive, Branford
Azitra Inc Aktie (AZTR) Neueste Nachrichten
Azitra to Present at BIO-Europe 2024 - BioSpace
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com
Azitra Joins 2024 Maxim Healthcare Virtual Summit - FinancialNews.co.uk
Netherton Syndrome Treatment Industry is Expected to Reach $8 Billion by 2034 -Lifemax Laboratories, Azitra, Inc, Sixera – IndiaPolitics.com - IndiaPolitics.com
Azitra stock plunges to 52-week low, hits $0.49 By Investing.com - Investing.com South Africa
Azitra stock plunges to 52-week low, hits $0.49 - Investing.com
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Australia
Azitra to present EGFR inhibitor toxicity treatment data - Investing.com India
AZTRAzitra Inc Latest Stock News & Market Updates - StockTitan
Mexico's inflation undershoots forecasts ahead of rate decision - Investing.com
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire
AZTR’s Market Fluctuations: Is Now the Right Time to Invest? - The InvestChronicle
FDA fast tracks Azitra's new dermatology treatment - Investing.com
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - StockTitan
Taking a Closer Look At Azitra Inc (AZTR) Following Its Recent Trade - Knox Daily
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Azitra (NYSEAMERICAN:AZTR) Stock Price Down 7.8% - Defense World
Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update - Defense World
Azitra Inc’s latest rating changes from various analysts - Knox Daily
A significant driver of top-line growth: Azitra Inc (AZTR) - SETE News
Financial Metrics Exploration: Understanding Azitra Inc (AZTR) Through Ratios - The Dwinnex
Do investors need to be concerned about Azitra Inc (AZTR)? - US Post News
Azitra doses first subject in Phase Ib Netherton syndrome treatment trial - Yahoo Finance
Azitra begins phase 1b trial for Netherton syndrome treatment - Investing.com
Views of Wall Street’s Leading Experts on Azitra Inc - SETE News
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Trading Day Triumph: Azitra Inc (AZTR) Ends at 0.71, a -5.08 Surge/Plunge - The Dwinnex
Azitra Inc [AZTR] stock for 10,034 USD was bought by Staskey Norm - Knox Daily
FDA clears Azitra's Phase 1/2 trial for skin rash treatment - Investing.com
Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Marketscreener.com
A Look at Azitra Inc (AZTR) Shares in the Recent Past Indicates Growth - SETE News
Investing in Azitra Inc (AZTR) Is Getting More Attractive - Knox Daily
Azitra Inc Inc. (AZTR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Understanding AZTR stock ratios for better investment decisions - US Post News
Ratio Revelations: Azitra Inc (AZTR)’s Financial Metrics in the Spotlight - The Dwinnex
Azitra screens first subject in Phase Ib trial of ATR-12 for Netherton syndrome - Clinical Trials Arena
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Azitra, Inc. Announces First Patient Screened and Scheduled to Enroll in Phase 1B Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Azitra (NYSEAMERICAN:AZTR) Issues Earnings Results - Defense World
Stock Performance Spotlight: Azitra Inc (AZTR) Ends the Day at 0.70, Up by 2.94 - The Dwinnex
Azitra Inc’s Banking’s 100-Day Moving Average at 4.5289: Will the Stock Break Through? - The InvestChronicle
Get in on Azitra Inc’s (AZTR) buy-in window today! - SETE News
Checking in on Azitra Inc (AZTR) after recent insiders movement - Knox Daily
why Azitra Inc [AZTR] is a Good Choice for Investors After New Price Target of $3.50 - The DBT News
Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates - Marketscreener.com
Finanzdaten der Azitra Inc-Aktie (AZTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.11%
0.50%
Kapitalisierung:
|
Volumen (24h):